The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma. ©2005 The Japanese Society of Hematology.
CITATION STYLE
Ochiai, N., Yamada, N., Uchida, R., Fuchida, S. I., Okano, A., Hatsuse, M., … Shimazaki, C. (2005). Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. International Journal of Hematology, 82(3), 243–247. https://doi.org/10.1532/IJH97.05049
Mendeley helps you to discover research relevant for your work.